- US12564593utility2026Topical Formulation for a JAK Inhibitor0 cites
- US12544381utility2026Topical Formulation for JAK Inhibitor0 cites
- US12534463utility2026Substituted Tricyclic Compounds as FGFR Inhibitors0 cites
- US12247020utility2025Bipyrazole Derivatives as JAK Inhibitors0 cites
- US12226419utility2025Topical Formulation for a JAK Inhibitor0 cites
- US12227502utility20251h-pyrrolo[2,3-c]pyridin-7(6h)-ones and Pyrazolo[3,4-c] Pyridin-7(6h)-ones as Inhibitors of BET Proteins0 cites
- US12201636utility2025Heterocyclylamines as PI3K Inhibitors0 cites
- US12151026utility2024Sustained Release Dosage Forms for a JAK1 Inhibitor0 cites
- US12152033utility2024Use of Pyrazolopyrimidine Derivatives for the Treatment of Pi3k-δ Related Disorders0 cites
- US12024522utility2024Salts and Processes of Preparing a PI3K Inhibitor0 cites
- US11999751utility2024Bicyclic Heteroarylaminoalkyl Phenyl Derivatives as PI3K Inhibitors0 cites
- US11905275utility2024Bipyrazole Derivatives as JAK Inhibitors0 cites
- US11851442utility2023Tricyclic Fused Thiophene Derivatives as JAK Inhibitors0 cites
- US11840534utility2023Substituted Tricyclic Compounds as FGFR Inhibitors0 cites
- US11819505utility2023Heterocyclylamines as PI3K Inhibitors0 cites
- US11744832utility2023Heteroaryl Substituted Pyrrolo[2,3-b]pyridines and Pyrrolo[2,3-b]pyrimidines as Janus Kinase Inhibitors0 cites
- US11702416utility20231h-pyrrolo[2,3-c]pyridin-7(6h)-ones and Pyrazolo[3,4-c]pyridin-7(6h)-ones as Inhibitors of BET Proteins0 cites
- US11667635utility2023Bicyclic Heterocycles as FGFR4 Inhibitors0 cites
- US11590136utility2023Topical Formulation for a JAK Inhibitor0 cites
- US11576864utility2023Sustained-release Dosage Forms of Ruxolitinib0 cites
Page 1 of 2Next →